Trial Profile
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Somavaratan (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Acronyms VISTA
- Sponsors Versartis
- 07 Mar 2018 Status changed from active, no longer recruiting to discontinued.
- 18 Jan 2018 This trial has been discontinued in Poland (end date: 7 Nov 2017).
- 09 Nov 2017 This trial has been discontinued in Sweden.